Mumbai, October 1, 2026: With cancer cases continuing to rise and oncology rapidly evolving  through scientific and technological advancements, Nanavati Max Super Speciality Hospital will host Max Cancer Congress 2026 on October 3 and 4. The two-day conference will bring  together more than 500 delegates, including leading oncology experts, clinicians, researchers  and healthcare professionals from across the country to deliberate on emerging trends, new  evidence and innovations shaping the future of cancer diagnosis, treatment and patient care. 

The conference comes against the backdrop of a growing cancer burden in India and  Maharashtra. According to recent estimates based on ICMR-NCDIR data, India recorded 15,69,793 new cancer cases in 2025, up from 14,26,447 cases in 2021. In Maharashtra alone the estimated number of new cancer cases increased to 1,30,465 in 2025, while the state  

continues to rank among those with the highest cancer incidence in the country. 

The programme will feature dedicated oncology sessions across Breast, Gastrointestinal,  Thoracic, Gynaecology, Head & Neck, Radiation, Haematology, Molecular & Genetics, and  Urology, highlighting emerging developments across the cancer care continuum. Discussions  will focus on multidisciplinary treatment approaches, precision oncology, molecular  diagnostics, immunotherapy, targeted therapies, robotic and minimally invasive surgery,  advanced radiation techniques, image-guided interventions and organ-preservation  strategies. 

Speaking about the event, Dr Ganesh Nagarajan, Vice Chairman – HPB & GI Surgery and Lead  – Growth & Strategy, Oncology, Nanavati Max Super Speciality Hospital, said, “The future of  cancer care will be shaped by how effectively different specialties work together. Max Cancer  Congress 2026 provides an important platform for experts to exchange knowledge, evaluate  emerging evidence and discuss innovations that can help improve patient outcomes across  the cancer care continuum.” 

Several sessions will examine advances that are reshaping cancer diagnosis and treatment,  including liquid biopsy, multi-cancer early detection, AI-assisted cancer care, molecular  tumour boards and precision medicine. Experts will also discuss evolving evidence across  various cancers, alongside newer approaches in CAR-T therapy, bispecific antibodies and stem  cell transplantation. 

Dr Muzammil Shaikh, Principal Director – Medical Oncology, Nanavati Max Super Speciality  Hospital, said, “Several breakthroughs that once seemed futuristic are now becoming part of  routine oncology practice. The growing role of immunotherapy, cellular therapies and AI enabled tools is creating new possibilities for improving cancer diagnosis, treatment selection  and long-term disease management.” 

Dr Hemant B. Tongaonkar, HOD & Principal Director – Urologic & Gynecologic Onco-surgery,  Nanavati Max Super Speciality Hospital, stated, “No two cancer patients are alike, and  treatment approaches are increasingly reflecting that reality. From molecular profiling to 

Press Release 

precision surgery, personalised treatment planning is helping clinicians make more informed  decisions and deliver better outcomes for patients.” 

A special Interventional Radiology masterclass on Irreversible Electroporation (IRE) will  explore patient selection, treatment techniques, clinical evidence and real-world case  discussions, providing participants with insights into the evolving role of advanced image guided interventions in cancer care. 

Dr George Karimundackal, Principal Director – Thoracic Surgery, Nanavati Max Super  Speciality Hospital, observed, “Lung cancer remains one of the most challenging cancers  globally, making timely diagnosis and multidisciplinary management essential. The  integration of minimally invasive surgery, advanced imaging and precision therapies is helping  redefine treatment pathways and improve outcomes for thoracic cancer patients.” 

Dr Garvit Chitkara, Associate Director – Breast Oncology, Nanavati Max Super Speciality  Hospital, remarked, “Breast cancer care has undergone a remarkable transformation over  the past decade. Better screening strategies, advances in molecular diagnostics and  increasingly tailored treatment approaches are enabling clinicians to detect disease earlier  and deliver more precise, patient-centric care.” 

Dr Devendra Chaukar, Principal Director – Head & Neck Oncology, Nanavati Max Super  Speciality Hospital, added, “For patients with head and neck cancers, treatment success is  about much more than disease control. Preserving speech, swallowing function and overall  quality of life has become an equally important goal, and advances in organ-preservation  strategies are helping clinicians achieve that balance more effectively.” 

Dr Sameer Tulpule, Senior Director – Haematology & BMT (Adult), Nanavati Max Super  Speciality Hospital, said, “Haematological cancers are among the areas where advances in  cellular therapies, targeted treatments and stem cell transplantation are rapidly changing the  treatment landscape. The growing understanding of disease biology is enabling us to move  towards more personalised treatment strategies, while newer therapies such as CAR-T are  opening avenues for patients with difficult-to-treat and relapsed cancers.” 

With participation from experts across oncology disciplines and a strong focus on innovation,  evidence-based practice and collaboration, Max Cancer Congress 2026 will serve as a platform  to discuss the latest advances shaping the future of cancer care and strengthen  multidisciplinary approaches to cancer management. 

Through initiatives such as this, Nanavati Max Super Speciality Hospital remains committed  to fostering clinical excellence, facilitating knowledge exchange and encouraging the adoption  of advanced, patient-centric approaches that can improve cancer outcomes and expand  access to high-quality oncology care.